Equities

HLS Therapeutics Inc

HLS Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)3.30
  • Today's Change0.06 / 1.85%
  • Shares traded3.08k
  • 1 Year change-34.00%
  • Beta1.0418
Data delayed at least 15 minutes, as of Sep 18 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.

  • Revenue in CAD (TTM)80.08m
  • Net income in CAD-32.76m
  • Incorporated2018
  • Employees91.00
  • Location
    HLS Therapeutics Inc10 Carlson Court, Suite 701ETOBICOKE M9W 6L2CanadaCAN
  • Phone+1 (647) 495-9000
  • Fax+1 (647) 495-9000
  • Websitehttps://www.hlstherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.